Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Binge Eating Disorder

Sygnature has successfully developed and validated a new rat model of binge-eating disorder. Rats are given free access to normal rat diet and irregular access to chocolate for limited periods (2 h). After 3-4 weeks, robust binge-eating develops.

We have tested lisdexamfetamine, the first and only drug approved by the FDA for the specific treatment of binge-eating disorder, in our rodent model. Lisdexamfetamine preferentially reduces intake of highly palatable food in rats trained to binge-eat. The model can be used for acute or sub-chronic evaluation of test compounds.

The development of binge-eating disorder in rats given irregular, intermittent access to chocolate; and the effect of acute administration of lisdexamfetamine on food intake during a binge episode

n=5. *p<0.05, **p<0.01, ***p<0.001 versus the control group which were given
empty feeding jars instead of chocolate (data for the control group not shown)
n = 8.  Significant differences versus the vehicle-treated controls are denoted by * **p<0.01 and
***p<0.001. Lisdexamfetamine 0.3 mg/kg po reduced chocolate binging without simultaneously
reducing consumption of the standard diet. Lisdexamfetamine did not significantly alter 24 h body weight.

We have also developed a food-associated conflict test to measure compulsivity in binge-eating rats, and a delay-discounting model to evaluate impulsivity and intolerance of delayed reward in binge-eating rats. Both models have been validated with lisdexamfetamine and can be used to evaluate the compulsivity and impulsivity components of binge-eating disorder psychopathology.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.